Topline results from phase 2 Celia study of diranersen, first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Published: 2026-05-14 07:45:40 ET BIIB

Published on 05/14/2026 at 07:45 am EDT